Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.59)
# 819
Out of 4,944 analysts
84
Total ratings
54.41%
Success rate
23.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: In-Line | $3 → $2 | $2.70 | -25.93% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $57.33 | +72.68% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $18.05 | +149.31% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.53 | +40.68% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $3.08 | +62.34% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.29 | +138.91% | 2 | Dec 11, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $33.65 | +4.01% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $373.46 | -3.60% | 9 | Aug 8, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $438 → $515 | $395.92 | +30.08% | 18 | Aug 2, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $432.52 | -39.89% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.06 | +88.68% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $9.14 | +261.05% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $48.31 | -21.34% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $28.97 | +176.15% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $6.87 | +162.01% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.74 | +568.45% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $7.60 | +715.79% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $7.23 | +384.09% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $21.97 | +9.24% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $12.42 | +141.55% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.37 | +196.74% | 1 | Feb 5, 2020 |
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $2.70
Upside: -25.93%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $57.33
Upside: +72.68%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $18.05
Upside: +149.31%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.53
Upside: +40.68%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $3.08
Upside: +62.34%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.29
Upside: +138.91%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $33.65
Upside: +4.01%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $373.46
Upside: -3.60%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Outperform
Price Target: $438 → $515
Current: $395.92
Upside: +30.08%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $432.52
Upside: -39.89%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.06
Upside: +88.68%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $9.14
Upside: +261.05%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $48.31
Upside: -21.34%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $28.97
Upside: +176.15%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $6.87
Upside: +162.01%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.74
Upside: +568.45%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $7.60
Upside: +715.79%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $7.23
Upside: +384.09%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $21.97
Upside: +9.24%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $12.42
Upside: +141.55%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.37
Upside: +196.74%